Your browser doesn't support javascript.
loading
Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study.
Solitano, Virginia; Facheris, Paola; Petersen, Magnus; D'Amico, Ferdinando; Ortoncelli, Michela; Aletaha, Daniel; Olivera, Pablo A; Bieber, Thomas; Ramiro, Sofia; Ghosh, Subrata; D'Agostino, Maria Antonietta; Siegmund, Britta; Chary-Valckenaere, Isabelle; Hart, Ailsa; Dagna, Lorenzo; Magro, Fernando; Felten, Renaud; Kotze, Paulo Gustavo; Jairath, Vipul; Costanzo, Antonio; Kristensen, Lars Erik; Biroulet, Laurent Peyrin; Danese, Silvio.
Afiliação
  • Solitano V; Division of Gastroenterology and Gastrointestinal Endoscopy, IRCCS Ospedale San Raffaele, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy.
  • Facheris P; Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Petersen M; The Parker Institute, University of Copenhagen & Bispebjerg University Hospital, Copenhagen, Denmark.
  • D'Amico F; Division of Gastroenterology and Gastrointestinal Endoscopy, IRCCS Ospedale San Raffaele, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy.
  • Ortoncelli M; Medical Sciences Department, Dermatologic Clinic, University of Turin, Turin, Italy.
  • Aletaha D; Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • Olivera PA; Gastroenterology Department, CEMIC, Buenos Aires C1425ASS, Argentina; Zane Cohen Centre for Digestive Diseases-Lunenfeld-Tanenbaum Research Institute-Sinai Health System-Gastroenterology, Toronto, ON M5T 3L9, Canada.
  • Bieber T; Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany.
  • Ramiro S; Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Zuyderland Medical Center, Heerlen, the Netherlands.
  • Ghosh S; APC Microbiome Ireland, College of Medicine and Health, University College Cork, T12 E138 Cork, Ireland.
  • D'Agostino MA; Rheumatology Fondazione Policlinico Universitario A. Gemelli,IRCSS and Università Cattolica del Sacro Cuore, Rome, Italy.
  • Siegmund B; Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
  • Chary-Valckenaere I; Rheumatology department, Nancy University Hospital and UMR 7365 CNRS-UL, IMoPA, Nancy, France.
  • Hart A; St. Mark's Hospital, Greater London, UK.
  • Dagna L; IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy.
  • Magro F; CINTESIS@RISE, Faculty of Medicine of the University of Porto, Porto, Portugal.
  • Felten R; Centre d'Investigation Clinique, INSERM CIC-1434, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Service de Rhumatologie, Centre National de Référence des Maladies Autoimmunes (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Département Universitaire de Pharmacologie-Ad
  • Kotze PG; Health Sciences Postgraduate Program, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba 80215-901, Brazil.
  • Jairath V; Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada; Department of Epidemiology and Biostatistics, Western University, London, ON, Canada.
  • Costanzo A; Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences Humanitas University, Pieve Emanuele, Italy.
  • Kristensen LE; The Parker Institute, University of Copenhagen & Bispebjerg University Hospital, Copenhagen, Denmark.
  • Biroulet LP; Department of Gastroenterology, Nancy University Hospital, F-54500 Vandœuvre-lès-Nancy, France; Inserm, NGERE, University of Lorraine, F-54000 Vandœuvre-lès-Nancy, France; INFINY Institute, Nancy University Hospital, F-54500 Vandœuvre-lès-Nancy, France; FHU-CURE, Nancy University Hospital, F-5450
  • Danese S; Division of Gastroenterology and Gastrointestinal Endoscopy, IRCCS Ospedale San Raffaele, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy. Electronic address: sdanese@hotmail.com.
Autoimmun Rev ; 23(3): 103504, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38128748
ABSTRACT
BACKGROUND AND

AIMS:

The Pharmacovigilance Risk Assessment Committee (PRAC) proposed measures to address severe side effects linked to Janus kinase inhibitors (JAKi) in immune-mediated inflammatory diseases (IMID). Use of these medications in individuals aged 65 and older, those at high cardiovascular risk, active or former long-term smokers, and those with increased cancer risk should be considered only if no alternatives exist. Caution is advised when administering JAKi to patients at risk of venous thromboembolism. We aim to implement recommendations from regulatory guidelines based on areas of uncertainty identified.

METHODS:

A two-round modified Research and Development/University of California Los Angeles appropriateness methodology study was conducted. A panel of 21 gastroenterologists, dermatologists and rheumatologists used a 9-point Likert scale to rate the appropriateness of administering a JAKi for each proposed clinical scenario. Scores for appropriateness were categorized as appropriate, uncertain, or inappropriate. Two rounds were performed, each with online surveys and a virtual meeting to enable discussion and rating of each best practice.

RESULTS:

Round 1 involved participants rating JAKi appropriateness and suggesting descriptors to reduce uncertainty. Survey results were discussed in a virtual meeting, identifying areas of disagreement. In round 2, participants rated their agreement with descriptors from round 1, and the level of uncertainty and disagreement reduced. Age flexibility is recommended in the absence of other risk factors. Active counseling on modifiable risks (e.g., overweight, mild hyperlipidemia and hypertension) and smoking cessation is advised. Uncertainty persists regarding cancer risk due to various factors.

CONCLUSIONS:

We outlined regulatory guidance without a personalized evaluation of the patient's risk profile might lead to uncertainty and become an arid technicality. Therefore, we identified gaps and implemented PRAC recommendations to help health professionals in clinical practice.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Janus Quinases Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Janus Quinases Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article